The Latest Breaking News from biotechnology

The U.S.

While any area of biotech will be considered for funding, it is particularly looking for projects focused on agriculture and food

The guidelines circumvent challenges of using foreign genes to change crops profile

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…

  PDS Biotechnology (NASDAQ:PDSB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB), considered a proxy for the sector, shed close to 3 percent during the week.

Much of Australia's biotech sector is based in regional Australia, but a lack of adequate, but a lack of adequate infrastructure means country patients are still missing out on the early stages of groundbreaking trials.

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings: